Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR)

International Journal of Cancer

Volumn 140, Issue 3, 2017, Pages 565-574

  Nair Shalliker, Visalini ^a,b,c   Yap, Sarsha ^a   Nunez, Carlos ^a   Egger, Sam ^a   Rodger, Jennifer ^a   Patel, Manish I ^b,d   O'Connell, Dianne L ^a,b,e   Sitas, Freddy ^b,f,g   Armstrong, Bruce K ^b,h   Smith, David P ^a,b,i  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g University of Sydney   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ GRIFFITH UNIVERSITY   (Australia)

Author keywords

balding; obesity; Prostate cancer; puberty; sexual activity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACNE; ADULT; AGED; ARTICLE; ASTHMA; BIRTHPLACE; BODY MASS; BODY SIZE; CANCER RISK; CIRCUMCISION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FAMILY HISTORY; HAIR LOSS; HOUSEHOLD INCOME; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW SOUTH WALES; OBESITY; ORGASM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT; SEXUAL INTERCOURSE; VASECTOMY; VERY ELDERLY; CASE CONTROL STUDY; LIFESTYLE; PHYSIOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; SEXUALITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BODY SIZE; CASE-CONTROL STUDIES; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NEW SOUTH WALES; PROSTATIC NEOPLASMS; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT; SEXUAL PARTNERS; YOUNG ADULT;

EID: 84998706914     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30471     Document Type: Article

References (41)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
3. Hennis AJ, Wu SY, Nemesure B, et al. Urologic characteristics and sexual behaviors associated with prostate cancer in an african-Caribbean population in barbados, west indies. Prostate Cancer 2013;2013:682750
4. Jiang J, Li J, Yunxia Z, et al. The role of prostatitis in prostate cancer: meta-analysis. PLoS One 2013;8:e85179
5. Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One 2011;6:e27130
6. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol 2009;6:87–95.
7. Turati F, Edefonti V, Bosetti C, et al. Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol 2013;24:2651–6.
8. Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 2013;68:937–43.
9. Barba M, Terrenato I, Schunemann HJ, et al. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study. Urology 2008;72:183–7.
10. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72–9.
11. Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:549–53.
12. Giles GG, Severi G, English DR, et al. Early growth, adult body size and prostate cancer risk. Int J Cancer 2003;103:241–5.
13. Giles GG, Severi G, English DR, et al. Sexual factors and prostate cancer. BJU Int 2003;92:211–6.
14. Habel LA, Van Den Eeden SK, Friedman GD. Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. Prostate 2000;43:136–43.
15. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39–66.
16. Brass AL, Barnard J, Patai BL, et al. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 1995;55:3197–203.
17. Sciarra F. Sex steroids and epidermal growth factor in benign prostatic hyperplasia (BPH). Ann N Y Acad Sci 1995;761:66–78.
18. Cobb JE, Zaloumis SG, Scurrah KJ, et al. Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. Exp Dermatol 2010;19:1026–8.
19. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001;116:452–5.
20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.
21. Hsu B, Cumming RG, Blyth FM, et al. The longitudinal relationship of sexual function and androgen status in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2015;100:1350–8.
22. Sitas F, Yap S, Egger S, et al. The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): Rationale and design of an unmatched “case-spouse control” study of over 10,000 participants in New South Wales, Australia. Cancer. Epidemiol 2015;39:414–23.
23. Australian Bureau of Statistics. ASGC Remoteness Classifi cation: purpose and use.Canberra:Commonwealth of Australia 2003. Date accessed: 1/4/2016.
24. World Health Organization on Physical Status. The Use and Interpretation of Physical status: the Use and Interpretation of Anthropometry Physical Status: the use of anthropometry: report of a WHO expert committee. 854. 1995. WHO technical report series 854.
25. Zhou CK, Pfeiffer RM, Cleary SD, et al. Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol 2015;33:419–25.
26. Muller DC, Giles GG, Sinclair R, et al. Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22:209–15.
27. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer–a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:1665–71.
28. World Cancer Research Fund International. Diet, nutrition, physical activity and prostate cancer-Continuous Update Project. Eur Urol. 2015. Date accessed: 1/4/2016
29. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer 2012;131:1711–9.
30. Moller E, Adami HO, Mucci LA, et al. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control 2013;24:2143–55.
31. Zuccolo L, Harris R, Gunnell D, et al. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008;17:2325–36.
32. Spence AR, Rousseau MC, Parent ME. Sexual partners, sexually transmitted infections, and prostate cancer risk. Cancer Epidemiol 2014;38:700–7.
33. Dimitropoulou P, Lophatananon A, Easton D, et al. Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int 2009;103:178–85.
34. Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett 2013;334:28–33.
35. Inui S, Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci 2011;61:1–6.
36. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899–911.
37. Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010;118:246–51.
38. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141–51.
39. Banks E, Redman S, Jorm L, et al. Cohort profile: the 45 and up study. Int J Epidemiol 2008;37:941–7.
40. Zhou CK, Littman AJ, Levine PH, et al. Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study. Prostate 2015;75:415–23.
41. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009;339:b4817